Compare IRMD & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | AVLN |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2026 |
| Metric | IRMD | AVLN |
|---|---|---|
| Price | $94.78 | $28.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $116.00 | N/A |
| AVG Volume (30 Days) | 113.2K | ★ 413.8K |
| Earning Date | 05-01-2026 | N/A |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $83,814,000.00 | N/A |
| Revenue This Year | $12.38 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $208.58 | ★ N/A |
| Revenue Growth | ★ 14.43 | N/A |
| 52 Week Low | $56.20 | $24.90 |
| 52 Week High | $107.90 | $33.32 |
| Indicator | IRMD | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 41.88 |
| Support Level | $90.12 | $27.22 |
| Resistance Level | $97.63 | $29.59 |
| Average True Range (ATR) | 3.12 | 1.94 |
| MACD | -0.51 | 0.21 |
| Stochastic Oscillator | 30.51 | 62.25 |
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.